Contact us

Contact us at the address, e-mail or telephone number below and we'll get back to you as soon as possible.

DAVID eHealth & Pharma UG,
Saarland University,
Starterzentrum, Building A1 1,
66123, Saarbruecken
Germany

This email address is being protected from spambots. You need JavaScript enabled to view it.

+49-151-51700933

Didn't we got you connected? Please note the following magic buttons:

Want to place your Ads or News on World Pharma News?

World Pharma News is one of the most visited sites on the Internet for pharmaceutical business decision-makers, professionals and stakeholders looking for the latest breaking news on the global market and in-depth research news articles. Why not put this traffic to work for you? It costs only a fraction of other on-line publications, which have far fewer readers.

We have the solutions that meet your ambitious marketing objectives. We offer flexible and price-worthy advertising opportunities for you to take advantage of. These include:

  • Skyscraper Banner, 120px / 600px (left-top, left-bottom)
  • Medium Rectangle Banner, 300px / 250px (right-top, medium and right-bottom)
  • Standard Banner, 468px / 60px (middle-top and middle-bottom)
  • Leaderboard Banner, 728px / 90px (top and bottom)
  • Newsletter Ads

The strong, innovative capabilities of World Pharma News can support your advertising, news promotion and news distribution campaigns. You will reach your objectives and an unique audience of top pharma professionals, key players and decision makers.

Don't Be Shy. If we didn’t answer all of your questions, feel free to drop us a line anytime.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Sanofi and Regeneron announce that cemiplimab (REG…

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemipli...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]